{"id":"https://openalex.org/W2182019407","doi":null,"title":"Dasatinib Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","display_name":"Dasatinib Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","alternate_titles":[],"publication_year":2008,"publication_date":"2008-01-01","ids":{"openalex":"https://openalex.org/W2182019407","mag":"2182019407"},"language":"en","primary_location":{"id":"mag:2182019407","doi":null,"is_oa":false,"landing_page_url":"https://link.springer.com/content/pdf/10.2165%2F00063030-200822010-00007.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2182019407"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079095462","display_name":"Adis Drug Profile","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Adis Drug Profile","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5022742209","display_name":"Susan J. Keam","orcid":"https://orcid.org/0000-0002-0121-7645","observed_orcids":["https://orcid.org/0000-0002-0121-7645"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Susan J. Keam","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0121-7645","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1829,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.5346874,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9490000009536743},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","score":0.9860000014305115},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.7670000195503235},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9290000200271606},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.968999981880188},{"id":"https://openalex.org/keywords/imatinib-intolerance","display_name":"imatinib intolerance","score":0.6850000023841858},{"id":"https://openalex.org/keywords/high-dose-imatinib","display_name":"high-dose imatinib","score":0.6660000085830688},{"id":"https://openalex.org/keywords/start-trial","display_name":"START trial","score":0.4519999921321869},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.7289999723434448},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.8709999918937683},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6700000166893005},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5789999961853027},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.5519999861717224},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.45100000500679016},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.33799999952316284},{"id":"https://openalex.org/keywords/bcr-abl-mutations","display_name":"BCR-ABL mutations","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9626864194869995},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7324574589729309},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.6769922375679016},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.5955175757408142},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.5357986688613892},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5277988314628601},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5222859382629395},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5141632556915283},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4757894277572632},{"id":"https://openalex.org/C125418893","wikidata":"https://www.wikidata.org/wiki/Q587961","display_name":"ABL","level":4,"score":0.4337235689163208},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.42699089646339417},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40998023748397827},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4019346833229065},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36340218782424927},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.34956568479537964},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14891424775123596},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11301663517951965},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.08944720029830933},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.07711321115493774},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2182019407","doi":null,"is_oa":false,"landing_page_url":"https://link.springer.com/content/pdf/10.2165%2F00063030-200822010-00007.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W1994309500","https://openalex.org/W2004492241","https://openalex.org/W2070683532","https://openalex.org/W2071999379","https://openalex.org/W2092606584","https://openalex.org/W2149468947","https://openalex.org/W2530803155"],"related_works":["https://openalex.org/W2032938895","https://openalex.org/W2032591088","https://openalex.org/W2564638997","https://openalex.org/W2151238788","https://openalex.org/W2550859769","https://openalex.org/W2162720854","https://openalex.org/W2575086792","https://openalex.org/W7098360964","https://openalex.org/W2579376724","https://openalex.org/W1586362467"],"abstract_inverted_index":{"\u25b2":[0,87,159,293],"Dasatinib":[1],"is":[2,54,303],"a":[3,299,324],"small-molecule":[4],"inhibitor":[5],"of":[6,21,47,84,92,110,127],"multiple":[7,128],"tyrosine":[8,129],"ki-":[9],"Indication":[10],"nases,":[11],"including":[12,59,131],"BCR-ABL,":[13,132],"SRC,":[14,133],"c-KIT,":[15,134],"ephrin":[16,135],"A":[17,136],"receptor":[18,34,146,151],"and":[19,42,75,79,90,140,147,171,187,260,273,279,347],"Treatment":[20],"adults":[22,105],"with":[23,106,162,185,202,212,222,228,255,264,283],"chronic,":[24],"accelerated,":[25],"or":[26,45,61,82,114,125,232,251,337],"blast":[27,77,248,257,266,335,344],"phase":[28,101,155,164,206,238,249,258,267,296,308,336,345],"(advanced":[29],"phase)":[30],"platelet-derived":[31,148],"growth":[32,149],"factor-\u03b2":[33,150],"kinases,":[35,130],"at":[36],"nanomolar":[37],"chronic":[38,107,163,307],"myeloid":[39,108,231,256,334],"leukemia":[40,73,112,119],"(CML)":[41,113],"resistance":[43,80],"to":[44,81,138,315,328],"intolerance":[46,83],"prior":[48,85],"therapy":[49,86],"concentrations.":[50],"In":[51,160],"vitro,":[52],"dasatinib":[53,94,142,203,223,301],"325-fold":[55],"more":[56],"potent":[57],"than":[58,204],"imatinib,":[60,139],"Philadelphia":[62,115],"chromosome":[63],"(Ph)-positive":[64],"acute":[65,117],"lymphoblastic":[66,118],"imatinib":[67,214],"against":[68],"cells":[69],"expressing":[70],"wild-type":[71],"BCR-ABL.":[72],"(ALL)":[74],"lymphoid":[76,233,265,338],"CML":[78,207,239,250,259,268,309,346],"The":[88],"efficacy":[89],"tolerability":[91],"oral":[93],"has":[95],"been":[96],"established":[97],"in":[98,104,154,175,188,226,246,262,281,306,331,361],"the":[99,166,176,189],"START":[100],"II":[102],"trials":[103,363],"Mechanism":[109],"action":[111],"chromosome-positive":[116],"(Ph-positive":[120],"ALL)":[121],"who":[122],"were":[123,145,224],"intolerant":[124],"Inhibitor":[126],"resistant":[137],"optimal":[141,305],"dosage":[143,195,311,351],"regimens":[144],"kinases":[152],"identified":[153],"III":[156,297],"randomized":[157,190],"trials.":[158],"patients":[161,227,282],"CML,":[165],"major":[167],"cytogenetic":[168],"res-":[169],"Dosage":[170],"administration":[172],"ponse":[173],"rate":[174],"START-C":[177],"trial":[178,192],"(median":[179,196],"follow-up":[180,197],"15.2":[181],"months)":[182],"was":[183,200],"59%":[184],"dasatinib,":[186],"START-R":[191],"Recommended":[193],"starting":[194],"15":[198],"months),":[199],"greater":[201],"Chronic":[205],"100":[208,312],"mg":[209,235,313,353],"once":[210,321],"daily":[211,237],"high-dose":[213],"(52%":[215],"vs":[216],"33%).":[217],"Major":[218],"hematologic":[219],"response":[220],"rates":[221],"63%":[225],"accelerated":[229,332],"Accelerated,":[230],"70":[234,352],"twice":[236],"(follow-up":[240,269,286],"\u22659":[241],"months;":[242,271,288],"START-A":[243],"trial),":[244],"34%":[245],"pa-":[247],"Ph-positive":[252,284,348],"ALL":[253,285,349],"tients":[254],"35%":[261],"those":[263],"\u226512":[270,287],"START-B":[272],"Administration":[274],"route":[275],"Oral":[276],"START-L":[277,289],"trials),":[278],"41%":[280],"trial).":[290],"Pharmacokinetic":[291],"profile":[292],"Based":[294],"on":[295],"results,":[298],"once-daily":[300],"regimen":[302,326],"considered":[304],"(starting":[310,350],"Time":[314],"peak":[316],"plasma":[317],"concentration":[318],"0.5\u20133":[319],"h":[320,343],"daily),":[322],"while":[323],"twice-daily":[325],"continues":[327],"be":[329],"recommended":[330],"phase,":[333],"Terminal":[339],"elimination":[340],"half-life":[341],"5\u20136":[342],"Most":[354],"frequent":[355],"drug-related":[356],"grade":[357],"3/4":[358],"adverse":[359],"events":[360],"clinical":[362]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2182019407","counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
